

Date: 30/10/2018

FREEDOM OF INFORMATION REQUEST - Ref: FOI/014418

I am writing to make several requests for information regarding your NHS Trust under the Freedom of Information Act:

- 1) Does your Trust have a policy on the use of unlicensed medicines? Please Answer Yes or No. If yes, please provide a copy of the policy and all other relevant documentation
- Yes for a copy of the policy please contact dgft.foi@nhs.net quoting reference number 014418
- 2) Does your Trust have a policy or protocol on obtaining informed consent from patients when an unlicensed medicine is used? Please answer Yes or No. If yes, please provide copies of all relevant documentation including copies of template informed consent materials used to consent patients where an unlicensed medicine is to be administered. Yes see response to question 2
- 3) Please state which Board level job role(s) is (are) responsible for patient safety and consenting Medical Director
- 4) Does your Trust have, or intend to introduce, a policy that makes compounded bevacizumab routinely available to treat wet age-related macular degeneration? If yes please supply a copy of your policy.

 No policy and no plans to introduce
- 5) Does your Trust currently have a wholly NHS owned pharmacy with an aseptic unit for compounding/aliquotting medicines? Please answer Yes or NO. If yes, is this NHS pharmacy the same legal entity as that of your hospital Trust?

Yes – aseptic unit is part of the NHS pharmacy for the organisation

- 6) Does your Trust currently host on its premises a privately owned pharmacy with an aseptic unit for compounding/aliquotting medicines? Please answer Yes or NO. If yes, please provide details of the third party provider of your pharmacy services. No
- 7) Over the past two years has your Trust, on more than one occasion, used compounded Avastin (bevacizumab) for ophthalmic use? Please answer Yes or No. No If you answered yes to Q5 or Q6:
- 8) Is the pharmacy referred to above in Q5 or Q 6 currently providing, or potentially able to provide, compounded Avastin (bevacizumab) for ophthalmic use? Please answer Yes or No No
- 9) Does the pharmacy referred to above in Q5 or Q6 currently hold an MHRA license for the manufacture of specials? Please answer Yes or No No If you answered yes to Q5 or Q6 but no to Q9:
- 10) When was the pharmacy referred to above in answer to Q5 or Q6 last inspected by the CQC? 28th June 2018

If you answered no to questions Q5 or Q6 above, but yes to question Q7:

11) Please provide information regarding from whom your Trust has or obtained/purchased compounded Avastin (bevacizumab). If you cannot provide the name of any commercial supplier, please provide as much information as possible. - N/A